Wasatch BioLabs (WBL) is an independent biotechnology company with a disruptive approach to research and diagnostics. We are an R&D and Oxford Nanopore Technologies-certified laboratory that offers DNA and RNA sequencing services to researchers and clinical service providers. WBL’s solutions span both standard Oxford Nanopore Technologies sequencing services as well as proprietary methylation sequencing services built off of WBL’s NESSI-Seq platform, that expand the capabilities of the nanopore platform. | Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows—translating breakthrough discovery into real-world outcomes.
Vazyme International LLC
Vazyme (688105.SH) is a global biotech supplier dedicated to advancing life science through innovative enzyme technology. To meet the varying needs of our customers and partners, we have developed over 1,000 types of genetically engineered recombinant enzymes, over 3,000 types of high-performance materials, and nearly 3,000 end products. By upholding rigorous quality standards and producing all molecular materials in-house, we guarantee a consistent and dependable supply to our global customers.
University of Helsinki
Launched in 2017, FinnGen is a wide public–private partnership coordinated by the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki. Leveraging Finland’s unique founder population and nationwide electronic health registers, FinnGen has now generated genome-wide data for more than 500 000 Finnish biobank participants (~10 % of the population) and linked these to >2 500 meticulously curated longitudinal disease endpoints. The combination of a semi-isolated population history, severe historical bottlenecks and rapid recent expansion enriches rare, high-impact alleles, allowing FinnGen to detect gene–disease associations with significantly fewer carriers than required in more heterogeneous cohorts and to provide rapid human-genetics validation for therapeutic targets. Published analyses have already revealed coding-variant effects across common and rare diseases, underscoring the power of this resource for both disease-mechanism discovery and drug-development pipelines. In addition to the health register data, FinnGen has recently included extensive laboratory measurement data collected on most of the FinnGen participants into national electronic health records from 2014 onward. The data have been harmonised and adapted to international standards to facilitate the straightforward use of the data in research. The latest public data freeze contains 21.3 million imputed variants and is fully accessible, free of charge, to researchers worldwide via online tools such as FinnGen PheWeb, Risteys portal and direct Google Cloud downloads after a simple webform. FinnGen is now expanding toward integrated proteomic, single-cell and other omic layers (FinnGen 3, 2023–2027) while maintaining annual freezes; the open dataset available to the community will therefore continue to grow. During the following years, the project will continue its search for genetic clues to disease progression and explore the biological mechanism of the genetic signals uncovered in the first stages of the project. While disease-specific studies often provide deeper phenotyping for individual conditions, FinnGen’s harmonized longitudinal data enables unprecedented insights across the full spectrum of health and disease. We continue to work with partners worldwide to develop new methodologies and demonstrate novel analyses possible with this rich data resource. Visit our booth at ASHG 2025 to explore how FinnGen’s harmonised genomic and registry framework can accelerate your research—from population genetics to target prioritisation—and join the thousands of researchers already using our data and/or summary lever results.
Ultima Genomics
At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The UG 100™ sequencer replaces complex and expensive flow cells with a 200mm open wafer to unlock multiple improvements that reduce cost, increase performance, and provide a roadmap for scalability. Automated wafer handling enables 24/7 continuous operation for flexible, high throughput labs. Our ppmSeq™ technology delivers Q60 SNV accuracy useful for liquid biopsy, MRD, somatic mosaicism, and other emerging applications on the UG 100™. | At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. To achieve this, we built a revolutionary new sequencing architecture that scales far beyond conventional technologies, enabling scientists to overcome the tradeoffs they face between the breadth, depth, and frequency of sequencing.
TruDiagnostic
TruDiagnostic Most biomarkers tell you where a patient is right now. DNA methylation tells you where they’re headed and why. TruDiagnostic is a CLIA-certified epigenetics lab and research partner specializing in DNA methylation analysis for biological age, disease risk, and multi-system health performance. Founded in 2020, we’ve built one of the largest private methylation datasets in the world: 200,000+ participants, 80+ published studies, and 115+ active research collaborators – including institutions publishing in Nature Aging and peer-reviewed clinical journals. Our positioning is deliberate: science over commercialization. Every product we offer is grounded in rigorous, independently validated research. What we bring to the table for our partners: Our Epigenetic Biomarker Proxies (EBPs) predict 2,000+ protein and metabolite biomarkers directly from a blood spot. In head-to-head comparisons, these DNA Methylation derived biomarkers outperform traditional direct measurements 62% of the time, with better effect sizes and greater signal stability. Unlike point-in-time assays, methylation patterns reflect long-term biological averages, making them less susceptible to day-to-day biological noise. Our Methylation Risk Scores (MRS) predict 5- and 10-year disease risk with ~90% accuracy across cardiovascular disease, diabetes, Alzheimer’s, Parkinson’s, and cognitive decline. Unlike polygenic risk scores, MRS are modifiable — they respond to interventions, making them uniquely actionable for clinical trials, therapeutic validation, and personalized medicine applications. Our immune deconvolution platform reconstructs cell-type composition from whole blood with only a 3% error rate compared to flow cytometry, at a fraction of the cost and complexity. We collaborate across pharma, consumer health, and clinical research. Deliverables include processed IDAT files and beta values, custom aging clocks, organ-specific risk scores, cohort-level analysis reports, and intervention efficacy assessments. Our work with Olaplex on tissue-specific skin aging demonstrates how this technology extends well beyond blood. If you’re running clinical trials, building risk stratification tools, or looking for a methylation data partner with the depth to support real discovery, we’re built for that conversation.
Tecan
At Tecan we are driven to improve people’s lives and health. We do this by empowering our customers to scale healthcare innovation globally from life science to the clinic. We collaborate with our customers in healthcare and the life sciences, from early-stage innovation through project implementation and beyond. We deliver the products, services and solutions that make lab processes and medical procedures precise, reproducible and compliant. This leads to scalable outcomes that are further reaching and ever more valuable to humankind. | Tecan is a global leader in life sciences and diagnostics, offering cutting-edge solutions that span genomics, automation, and personalized medical research. With a strong focus on workflow integration, Tecan delivers modular platforms and reagents that support every step of the genomics pipeline—from nucleic acid purification and quantification to PCR setup and next-generation sequencing (NGS) library preparation. Tecan’s automation systems, including MagicPrep® NGS and DreamPrep® NGS, provide walkaway solutions that simplify complex protocols, reduce errors, and increase throughput. These platforms enable broad and targeted genomic applications, which streamlines sequencing workflows for infectious disease and oncology research. Tecan’s commitment to standardization, scalability, and sustainability makes it a trusted partner for academic, clinical, and industrial research labs worldwide. By integrating automation with advanced reagents and collaborative development, Tecan is helping transform research into real-world medical impact. | Tecan supports the full product journey for complex MedTech, IVD, and life science systems, from critical components through development and manufacturing. Our teams specialize in high-mix, high-complexity programs that require disciplined processes and dependable execution. Through our contract manufacturing capabilities, we combine structured design transfer and vPoke® computer-directed assembly to deliver consistent results from pilot builds through scale. In parallel, our Cavro® components team provides precision liquid handling solutions that form the foundation of many complex instruments. With manufacturing in the US and Malaysia, FDA-approved facilities, and decades of experience across regulated industries, Tecan helps teams move forward with confidence, predictability, and long-term support. | Tecan is uniquely qualified to solve your most difficult technology and product-design problems. Our approach blends fundamental science and engineering to deliver limitless technology development. We take your ideas from concept to advanced functional prototype quickly, accurately and cost-effectively with our fixed price engagement model.
SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.
seqWell, Inc.
seqWell creates scalable genomics technologies that simplify NGS library preparation workflows and helps scientists to unlock transformative discoveries with sequencing. seqWell technology is focused on a novel, next-generation transposase, TnX™, to drive the scalability and high-performance needs of tagmentation and advance NGS. seqWell offers a range of library prep products, fragmentation workflows and sequencing services that allow customers to quickly and easily scale their short- and long-read sequencing initiatives. Learn more at www.seqwell.com or follow us on Linkedin.
SeqOne
SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under HIPAA as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. | SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.